Daratumumab/dexamethasone/selinexor: Lack of efficacy: 3 case reports.

In a study of 8 patients with relapsed/refractory multiple myeloma, three patients exhibited a lack of efficacy during treatment with selinexor, daratumumab, and dexamethasone. The patients, aged between 44-78 years, had previously received treatment with lenalidomide. Despite receiving the combination treatment, their disease progressed, indicating a lack of effectiveness. This information is based on a single-arm, prospective, non-interventional, real-world study conducted between February and May 2023. [Extracted from the article]